全球IL4Rα阻塞在小鼠和人类缺血事件后加剧心力衰竭
Santiago Alvarez-Argote1,2, Victor A Almeida1,2, Makenna C Knas1,2
1Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States.
概括
介素-4受体α (IL4Rα) 信号保护小鼠和人类心肌梗塞后的心力衰竭. 用dupilumab阻止IL4Rα会增加患有缺血性心脏病的患者心力衰竭的风险.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性心力衰竭是一种普遍的疾病,正在研究疾病进展机制.
- 干白素-13 (IL13) 和干白素-4 (IL4) 信号传递与小鼠心肌梗塞后的改善结果有关.
- 杜皮卢马布是一种抑制IL4/IL13受体亚单元IL4Rα的抗体,在临床上用于其他疾病.
研究的目的:
- 研究IL4Rα信号在缺血性心力衰竭中的作用.
- 确定全球IL4Rα缺失对小鼠心肌梗塞后心脏功能的影响.
- 评估在患有缺血性心脏病的患者中使用dupilumab和心力衰竭风险之间的关联.
主要方法:
- 成年小鼠中IL4Rα的遗传删除,随后是手术诱导的心肌梗塞 (MI).
- 在小鼠中评估心脏功能障碍和毛细血管大小.
- 使用TrinetX网络和dupilumab使用数据,分析患有缺血性心脏病的患者心力衰竭风险.
主要成果:
- 全球IL4Rα删除在MI后的小鼠中加剧了心脏功能障碍和毛细血管尺寸的减少.
- 在患有先前缺血性心脏病的患者中,杜皮卢马布治疗与心力衰竭风险显著增加有关.
- 系统IL4Rα信号似乎在小鼠和人类的缺血事件后保护心力衰竭.
结论:
- 系统IL4Rα信号保护心肌缺血后心力衰竭的发生.
- 在患有缺血性心脏病的患者中,dupilumab的使用可能会增加心力衰竭风险.
- 通过随机临床试验进行进一步的调查是有必要的,以证实这些发现.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
338
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
338
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K